New microneedle patch delivers full dose; Mesothelioma drug delivered via skin; MultiCell, Genisphere partner in RNA arena;

> Researchers at the University of North Carolina at Chapel Hill have developed a microneedle patch with a dissolvable backing that helps deliver a full dose of medication, leaving the needles in place for a longer amount of time. News

> Researchers at Griffith University in Australia are creating a mesothelioma treatment that can be delivered via the skin. More

> MultiCell Technologies and Genisphere are collaborating to develop a targeted nanoparticle treatment for liver cancer. The noncoding double-stranded microRNA is called MCT-485. Release

> Enteris BioPharma launched its business, operational and development arm to extend its recently acquired Peptelligence nasal delivery platform into small molecule therapeutics. Enteris bought the technology from Unigene Laboratories ($UGNE). Release

> Serina Therapeutics has partnered with the Scripps Research Institute to develop polymer-antibody drug conjugates able to deliver a potent cytotoxic agent. More

> Kemwell Biopharma out of Bangalore acquired American CRO and development company Cirrus Pharmaceuticals, which focuses on inhaled, nasal, oral, parenteral, topical and transdermal products. Article

> MedPharm scored a new patent for its MedSpray topical spray-on film for dermatological, topical and transdermal drug delivery. Release

Suggested Articles

J&J figures its partner Genmab owes a share of Darzalex Faspro royalties to Halozyme for its subcutaneous delivery tech. Genmab doesn't agree.

Bexson Biomedical and Stevanato Group teamed up to develop a ketamine pump that may help patients better manage pain at home.

Australia's University of New South Wales and Uka Tarsadia University in India will join forces to explore contact lenses for ocular drug delivery.